Rvx 208.
Drugs in R&D（2011）
摘要
RVX 208 (RVX-208; RVX000222) is a first-in-class novel small molecule in development by Resverlogix Corporation for acute coronary syndromes, atherosclerosis and Alzheimer disease. It increases the levels of apolipoprotein A1 and high-density lipoprotein cholesterol, thereby potentially reducing the risk for cardiovascular disease. This review discusses the key development milestones and therapeutic trials of this drug. This summary has been extracted from Wolters Kluwer's R&D Insight drug pipeline database. R&D Insight tracks and evaluates drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch. This is an open access article published under the terms of the Creative Commons License "Attribution-NonCommercial-NoDerivative 3.0" (http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits non-commercial use, distribution, and reproduction, provided the original work is properly cited and not altered.
更多查看译文
关键词
lipoprotein particles containing apoa-i,atherosclerosis,lpa-i,cetp,reverse cholesterol transport,fractional cholesterol esterification rate,mrna,african green monkey,hdl,hdl-based therapy,2-dimensional polyacrylamide non-denaturing gradient gel electrophoresis,lcat,2d-pagge,scavenger receptor class b type i,abca1,adenosine triphosphate binding cassette ai,lecithin:cholesterol acyl transferase,acvd,high-density lipoprotein cholesterol,high-density lipoprotein,agm,baby hamster kidney,rct,non-denaturing gradient gel electrophoresis,atherosclerotic cardiovascular disease,hdl-c,adenosine triphosphate binding cassette gi,ldl-c,low-density lipoprotein cholesterol,fer,pltp,nd-pagge,bhk,apo,sr-bi,cholesteryl-ester-transfer protein,messenger ribonucleic acid,abcg1,apoa-i,apolipoprotein,phospholipid transfer protein
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要